drugset / Trial / NCT00576823
Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Primary objective was to determine efficacy of Alfuzosin in the treatment of children and adolescents 2-16 years of age with newly diagnosed or progressive hydronephrosis due to elevated detrusor Leak Point Pressure \[LPP\] of neuropathic etiology. Secondary objectives were: * To investigate the safety and tolerability of alfuzosin 0.2 mg/kg/day in children and adolescents, * To investigate the number of Urinary Tract Infection (UTI) episodes, * To investigate the pharmacokinetics of Alfuzosin (population kinetics).
Timeline
- Start
- 2007-12
- Primary completion
- 2009-01
- Completion
- 2009-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alfuzosin | Small molecule | 0.2 mg/kg | Oral |